On February 22, 2024, the board of directors of Zymeworks Inc., upon recommendation from the nominating and corporate governance committee of the Board, appointed Mr. Scott Platshon, Partner of EcoR1, as a director of the Company, effective as of February 22, 2024. Mr. Platshon was appointed as a Class III director with a term expiring at the Company?s 2024 annual general meeting of stockholders. Mr. Platshon will not be named to any committees of the Board in connection with his appointment.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.4 USD | -0.12% |
|
-1.64% | -19.15% |
Jun. 17 | Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy | MT |
Jun. 17 | Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.15% | 599M | |
+17.20% | 121B | |
+21.21% | 114B | |
+18.05% | 23.61B | |
-17.80% | 20.43B | |
-16.24% | 16.55B | |
-10.99% | 16.45B | |
-44.45% | 15.59B | |
+69.81% | 15.19B | |
+2.08% | 13.54B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc. Appoints Scott Platshon as Director